Cancer Prostate Cancer
| Publication Date | March 2008 |
|---|---|
| Publisher | Life Science Analytics |
| Product Type | Report |
| Pages | 377 |
| ISBN Number | not applicable |
| Product Code | LSA02295 |
Summary
Life Science Analytics', Cancer Non-Small-Cell Lung Cancer or Lung Cancer or Small Cell Lung Cancer contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area.
Scope of the report:
Each Life Science Analytics' Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage, for each specific therapy area. The latest news, by company, also ensures that each report is fresh and up-to-date.
In addition to new developments and disease specific pipeline projects, each report also contains extensive information in tabular format on a company's full product pipeline and products by phase of development with regard to the therapy area.
Full pipeline details, by stage, are provided and include detailed product descriptions, information on partnering activity plus clinical trial intelligence. Each Therapy Area Pipeline Report also provides detail on the top 20 companies with products in the early stage of development and the top 20 companies with products in the late stage of development. Finally, each report also provides a comparison with other major indications in the disease hub based on Marketed Products vs. Pipeline Products.
Key benefits
- Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline for specific therapy areas.
- Keep track of your competitors and partners by better understanding their product pipeline.
- Monitor a company's research effectiveness by determining pipeline depth and number of products in development by clinical phase for specific disease areas.
- Maintain a critical competitive advantage.
Content
- Recent Highlights and Changes
- Upcoming Patent Expires by Therapy Area
- Non-Small-Cell Lung Cancer or Lung Cancer or Small Cell Lung Cancer Pipeline Overview
- % of Projects (by Phase of Development)
- No. of Projects by Phase of Development
- Marketed Products vs. Pipeline Products
- Company Overview - Pipeline Projects
- Company Overview - Pipeline Projects
- Top Companies in late stage Non-Small-Cell Lung Cancer or Lung Cancer or Small Cell Lung Cancer Projects
- Amgen Inc
- Abbott Laboratories
- Boehringer Ingelheim GmbH
- AstraZeneca Plc
- Celgene Corporation
- Bristol-Myers Squibb Company
- Eli Lilly & Co
- Eisai Co Ltd
- GlaxoSmithKline plc
- Genentech Inc
- Merck KGaA
- Imclone Systems Inc
- OXiGENE INC
- OSI Pharmaceuticals Inc
- Pharmacyclics Inc
- Pfizer Inc
- Roche Holdings Ltd
- PharmaMar
- Telik Inc
- Spectrum Pharmaceuticals Inc
- Top Companies in early stage Non-Small-Cell Lung Cancer or Lung Cancer or Small Cell Lung Cancer Projects
- Alfacell Corp
- Active Biotech
- AmpliMed Corporation
- Allos Therapeutics Inc
- Antisense Pharma GmbH
- Anavex Life Sciences Corp.
- Archemix Corp.
- Antisoma PLC
- Bristol-Myers Squibb Company
- Ariad Pharmaceuticals Inc
- LEO Pharma A/S
- Introgen Therapeutics Inc
- Medisyn Technologies, Inc.
- MEABCO A/S
- Peregrine Pharmaceuticals Inc
- Patrys Limited
- Silence Therapeutics plc
- erly SR Pharma plc)
- Raven biotechnologies, INC.
- Topotarget A/S
- Takeda Pharmaceutical Company Limited
- Pipeline Revenue
- Pipeline Revenue
- Full Pipeline View
- Pre Clinical Pipeline View
- Phase I Pipeline View
- Phase II Pipeline View
- Phase III Pipeline View
- Pending Approval Pipeline View
- Approved Pipeline View
- on the Market Pipeline View
- Discovery/Development Pipeline View
- Non-Small-Cell Lung Cancer or Lung Cancer or Small Cell Lung Cancer Pipeline Overview
About this Product
Delivery Details
PDF:Delivered by email usually within 4 to 8 UK business hours.
PRINT/CD-ROM:Despatched within 1 to 2 working days.
Related Products
- AstraZeneca’s Crestor Could Revolutionise Heart Disease Treatment >>
- Sanofi-Aventis and Pfizer Stop Development of a Class of Anti-obesity drugs >>
- Pharma Companies turn Webwards to Recruit Patients as 90% of Clinical Trials Face Delay >>
- Have your Healthcare Costs Reduced with Personalized Healthcare >>
Pharma & Healthcare
- Animal / Veterinary
- Biotechnology
- Cardiovascular
- Chemicals
- Company Financials
- Company Reports (Pharmaceutical)
- Country Reports (Pharmaceutical)
- Deals & Alliances
- Dental
- Diagnostics
- Dietary
- Diseases
- Drug Delivery
- Drug Discovery
- Finance / Investment
- General Industry
- Generic Drugs
- Healthcare
- IT & eHealth
- Management / Strategy
- Medical Devices
- Medical Supplies
- OTC drugs
- Pharmacy
- Prescription Drugs
- Production / Manufacturing
- Regulation & Policy
- Research (R&D)
- Sales & Marketing
- Technology
- Therapeutic
- Treatments
call +44 (0) 20 7060 7474
or email us
Resources
Why Report Buyer?
Advertising/Affiliates
View Our Publishers
News
About Us
Market Publishers
Meet Us
Jobs
Contact Us
Categories and Subcategories















